Irish investment firm Malin has invested $80m (€73m) in UK biotechnology firm Immunocore as part of Europe’s largest ever life sciences-focused funding round.

Elan agreed to pay $1bn (€770m) for a share of the royalties on new drugs from Theravance as it tries to persuade shareholders to spurn a takeover offer by Royalty Pharma.